QuidelOrtho Corp.

QuidelOrtho Corp. has recently revised its evaluation amid challenging market conditions, with its stock priced at $17.92. Over the past year, the company has seen a significant decline, contrasting sharply with the S&P 500's performance. Technical indicators suggest a prevailing bearish sentiment for the stock.

QuidelOrtho Corp. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company has reported negative results for 12 consecutive quarters, with a high debt-equity ratio and a low return on equity, highlighting ongoing financial challenges.

QuidelOrtho Corp. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company has struggled with negative profits for 12 consecutive quarters, a high debt-equity ratio, and a return on equity indicating ongoing financial challenges in the biotechnology sector.

QuidelOrtho Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. Current technical indicators suggest a bearish outlook, with significant declines in performance metrics over the past year and five years, reflecting ongoing challenges for the company amid market volatility.

QuidelOrtho Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has experienced significant stock fluctuations, with a recent closing price of $23.33. Over the past year, the company has underperformed compared to the S&P 500, reflecting ongoing challenges in a competitive market environment.

QuidelOrtho Corp. has faced notable stock volatility, with significant declines over various timeframes, including a 47.63% drop over the past year. Financial challenges are evident, including a negative pre-tax profit and a debt-to-equity ratio of 1.31, indicating ongoing pressures within the Pharmaceuticals & Biotechnology sector.

QuidelOrtho Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced notable stock fluctuations, with a recent closing price of $26.37. The stock's performance has lagged behind the S&P 500, reflecting challenges in a competitive market and the need for strategic adjustments.

QuidelOrtho Corp. has recently revised its evaluation amid challenging market conditions, with its stock priced at $29.60. Over the past year, the company has experienced a significant decline, contrasting with the S&P 500's gains. Technical indicators show mixed signals, reflecting ongoing volatility in its performance.

QuidelOrtho Corp. saw a notable stock price increase on September 30, 2025, reaching an intraday high. However, the company has struggled over the past year, with significant declines in performance and financial metrics, including a pre-tax profit loss and rising interest expenses, indicating ongoing challenges.

QuidelOrtho Corp. has recently revised its evaluation amid challenging market conditions, with its stock priced at $28.46. Over the past year, the company has experienced a significant decline, contrasting sharply with broader market gains. Technical indicators show mixed signals, reflecting ongoing performance struggles.